Abstract: For example, an apparatus may include a sensor configured to detect changes in an environment of a wireless communication device based on wireless communication signals communicated by the wireless communication device. For example, the sensor may include an input to receive signal information of a plurality of Receive (Rx) signals received by an Rx antenna of the wireless communication device based on a loopback of a plurality of wireless transmit (Tx) signals transmitted by a Tx antenna of the wireless communication device; and a processor configured to determine a detection result based on a change in the signal information between an Rx signal and at least one previous Rx signal of the plurality of Rx signals, the detection result to indicate a detected change in the environment of the wireless communication device.

Abstract: An antibody comprising an antigen recognition domain exhibiting species cross reactivity to human QSOX1 and murine QSOX1 is disclosed. Methods of producing the antibody, pharmaceutical compositions comprising the antibody and methods of using the antibody for treating medical conditions are also disclosed.

Abstract: An antibody comprising an antigen recognition domain exhibiting species cross reactivity to human QSOX1 and murine QSOX1 is disclosed. Methods of producing the antibody, pharmaceutical compositions comprising the antibody and methods of using the antibody for treating medical conditions are also disclosed.

Abstract: An antibody comprising an antigen recognition domain exhibiting species cross reactivity to human QSOX1 and murine QSOX1 is disclosed. Methods of producing the antibody, pharmaceutical compositions comprising the antibody and methods of using the antibody for treating medical conditions are also disclosed.

Abstract: A method of inhibiting or preventing laminin assembly in a basement membrane is disclosed. The method comprising contacting a tissue with an agent which inhibits QSOX1 activity or expression, thereby inhibiting or preventing laminin assembly in the basement membrane.

Abstract: A method of inhibiting or preventing laminin assembly in a basement membrane is disclosed. The method comprising contacting a tissue with an agent which inhibits QSOX1 activity or expression, thereby inhibiting or preventing laminin assembly in the basement membrane.

Abstract: A method of inhibiting or preventing laminin assembly in a basement membrane is disclosed. The method comprising contacting a tissue with an agent which inhibits QSOX1 activity or expression, thereby inhibiting or preventing laminin assembly in the basement membrane.

Abstract: A method for the diagnosis of schizophrenia in an individual comprises: (i) measuring mRNA of either D3 dopamine receptor or ?7 nicotinic acetylcholine receptor (?7 AChR), and of a control gene in peripheral blood lymphocytes (PBLs) of the individual and of at least one healthy control individual; (ii) calculating the ratio between the receptor mRNA and the control gene mRNA for each individual; and (iii) evaluating the ratio between the ratios obtained in (ii) for the tested individual and for the at least one healthy control individual, wherein (a) an increase in the D3 dopamine receptor mRNA or a decrease in the ?7 AChR in the tested individual in comparison to healthy individuals, indicates that said tested individual has a higher likelihood of having schizophrenia than the healthy controls.

Abstract: A method for the diagnosis and follow up of a mental disorder or of a neurodegenerative disorder in an individual, comprises: (i) measuring mRNA of D3 dopamine receptor and/or of ?7 nicotinic acetylcholine receptor (?7 AChR) and of a control gene in peripheral blood lymphocytes (PBLs) of said individual and of at least one healthy control individual; (ii) calculating the ratio between the D3 dopamine receptor mRNA and the control gene mRNA and/or the ratio between ?7 AChR mRNA and the control gene mRNA for each individual; and (iii) evaluating the ratio between the ratios obtained in (ii) for the tested individual and for the at least one healthy control individual, wherein an increase in the D3 dopamine receptor mRNA and/or a decrease in the ?7 AChR mRNA in the tested individual in comparison to healthy individuals, indicate that said tested individual has a high likelihood of having said mental disorder or neurodegenerative disorder, wherein said increase in the D3 dopamine receptor mRNA and/or decrease in

Abstract: A method for the diagnosis and follow up of a mental disorder or of a neurodegenerative disorder in an individual, comprises: (i) measuring mRNA of D3 dopamine receptor and/or of ?7 nicotinic acetylcholine receptor (?7 AChR) and of a control gene in peripheral blood lymphocytes (PBLs) of said individual and of at least one healthy control individual; (ii) calculating the ratio between the D3 dopamine receptor mRNA and the control gene mRNA and/or the ratio between ?7 AChR mRNA and the control gene mRNA for each individual; and (iii) evaluating the ratio between the ratios obtained in (ii) for the tested individual and for the at least one healthy control individual, wherein an increase in the D3 dopamine receptor mRNA and/or a decrease in the ?7 AChR mRNA in the tested individual in comparison to healthy individuals, indicate that said tested individual has a high likelihood of having said mental disorder or neurodegenerative disorder, wherein said increase in the D3 dopamine receptor mRNA and/or decrease in